Core Viewpoint - The RxSight class action lawsuit alleges that the company and its executives made misleading statements regarding the company's performance and financial guidance, leading to significant stock price declines [1][4][5]. Company Overview - RxSight is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery [3]. Allegations of the Lawsuit - The lawsuit claims that RxSight faced "adoption challenges" and structural issues that resulted in declining sales and utilization of its products [4]. - It is alleged that the company overstated the demand for its products, which contributed to its inability to meet previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second quarter financial results on July 8, 2025, which showed significant declines in sales and revenue, RxSight lowered its full year guidance by approximately $42.5 million at the midpoint [5]. Financial Impact - The lawsuit notes that RxSight's stock price fell nearly 38% following the announcement of disappointing financial results and guidance adjustments [5].

Core Insights - The Brown Capital Management Small Company Fund experienced an 8.59% return in Q2 2025, underperforming the Russell 2000® Growth index which returned 11.97% [1] - The underperformance was primarily noted in the last few weeks of the quarter [1] Fund Performance - Small-cap US stocks rebounded in Q2 2025 after a challenging first quarter [1] - The fund's top five holdings were highlighted as key picks for 2025 [1] Company Highlight: RxSight, Inc. - RxSight, Inc. (NASDAQ:RXST) is a commercial-stage medical device company specializing in light-adjustable intraocular lenses for cataract surgery [2] - RxSight, Inc. had a one-month return of 9.66%, but its shares have lost 83.24% of their value over the past 52 weeks [2] - As of September 12, 2025, RxSight, Inc. stock closed at $9.31 per share, with a market capitalization of $380.928 million [2] Performance Detractors - RxSight, Inc. was noted as one of the detractors to the fund's performance in Q2 2025, alongside Bio-Techne (TECH) [3]

Group 1 - The Gross Law Firm has issued a notice to shareholders of RxSight, Inc. regarding potential legal matters [1]

Core Viewpoint - A class action lawsuit has been filed against RxSight, Inc. for allegedly making false statements and failing to disclose significant issues affecting its sales and financial guidance during the specified class period [2][3][4]. Summary by Sections Class Action Lawsuit - The lawsuit is on behalf of all individuals and entities who purchased or acquired RxSight securities between November 7, 2024, and July 8, 2025 [2]. - Investors have until September 22, 2025, to apply to be appointed as lead plaintiff in the lawsuit [2]. Allegations Against RxSight - The lawsuit claims that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization [3]. - It is alleged that the company overstated the demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [3]. Financial Impact - On July 8, 2025, RxSight reported preliminary second-quarter financial results showing significant declines in Light Delivery Device (LDD) sales and overall revenue [4]. - The company lowered its full-year 2025 guidance by approximately $42.5 million at the midpoint, attributing the decline to adoption challenges [4]. - Following this announcement, RxSight's stock price fell nearly 38% [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RxSight, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the lawsuit is from November 7, 2024, to July 8, 2025, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 22, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that RxSight made false and misleading statements regarding its sales and utilization, overstated demand for its products, and was unlikely to meet its financial guidance for fiscal year 2025 [4]. - The misleading statements led to investor damages when the true details about the company's performance were revealed [4].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., No. 25-cv-01596, with investors having until September 22, 2025, to seek lead plaintiff status [2]. Financial Performance - RxSight experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors despite the company promoting strong sales [4]. - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast, leading to a 38% drop in stock price from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, resulted in another 38% decline in stock price from $12.79 to $7.95 per share [6].

Accessibility StatementSkip Navigation SAN DIEGO, Sept. 13, 2025 /PRNewswire/ --Robbins Geller Rudman & Dowd LLP announces that the RxSight class action lawsuit – captioned Makaveev v. RxSight, Inc., No. 25-cv-01596, and pending in the Central District of California – seeks to represent purchasers or acquirers of RxSight, Inc. (NASDAQ: RXST) securities and charges RxSight as well as certain of RxSight's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses ...

Group 1 - A class action has been filed on behalf of shareholders of RxSight, Inc. for securities purchased between November 7, 2024, and July 8, 2025 [1] - RxSight is identified as a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses [1]

Group 1 - RxSight, Inc. is under investigation for potential securities fraud claims following significant declines in sales and revenue [1][2] - The company reported a 37% drop in share price, closing at $7.95 per share after disclosing adoption challenges affecting LDD sales and LAL utilization [2] - Investors who acquired RxSight stock between November 7, 2024, and July 8, 2025, may seek lead plaintiff status in the ongoing litigation [3] Group 2 - RxSight specializes in medical technology, specifically developing light adjustable intraocular lenses (LAL) for cataract surgery [1] - The company's Light Delivery Device (LDD) is a key component of its RxSight system [1]

Core Viewpoint - A class action securities lawsuit has been filed against RxSight, Inc. for alleged securities fraud affecting investors between November 7, 2024, and July 8, 2025 [1][2]. Group 1: Allegations and Company Performance - The lawsuit claims that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization [2]. - It is alleged that the company overstated the demand for its products, which resulted in an inability to meet previously issued financial guidance for fiscal year 2025 [2]. - The positive statements made by the defendants regarding the company's business and prospects were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].